HDAC9 and plasma cell myeloma: Most of the HDAC inhibitors that are currently under investigation in clinical trials or have not been approved yet, such as panobinostat (approved for the therapy of multiple myeloma in 2015 by the EMA [57]), inhibit a broad variety of HDACs including HDAC2.